The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Cui, Jianlan ^a   Cai, Xueya ^b   Zhu, Min ^c   Liu, Tianshu ^a   Zhao, Naiqing ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c Shanghai Zhabei Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876163109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062038     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, et al. (2006) Cancer statistics. CA Cancer J Clin 56: 106-30.
2. Boyle P, Levin B, editors. (2008) World cancer report 2008. Lyon: IARC.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.2.2009. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed 2012 Sep 18.
4. Novello S, Le Chevalier T, (2003) Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncol (Williston Park) 17(3): 357-364.
5. Xue D, Zhou YB, (2008) Advancement in research of molecular target treatment in NSCLC. Int J Intern Med 35(7): 419-422.
6. Gridelli C, (2006) Targeted therapies and non-small cell lung cancer: work in progress? Current Opinion in Oncology 18: 132-134.
7. De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, et al. (2010) Consequences of targeted treatments for second-line therapy. Annals of Oncology 21(7): 234-240.
8. Yang K, Wang YJ, Chen XR, Chen HN, (2010) Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 30(4): 229-41.
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24): 2542-50.
10. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, et al. (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 25(30): 4743-50.
11. Reck M, Pawel JV, Zatloukal P, Ramlau R, Gorbounova V, et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-Line therapy for nonsquamous non-small-cell lung cancer AVAiL. J Clin Oncol 27(8): 1227-34.
12. NishioM, Horai T,KunitohH,IchinoseY,NishiwakiY,et al. Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8036 Accessed 2012 May 26.
13. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, et al. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-54.
14. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, et al. (2004) Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 22: 2184-2191.
15. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-28.
16. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, et al. (2004) Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial-INTACT 2. J Clin Oncol 22: 785-794.
17. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 362: 2380-8.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
19. Parmar MKB, Torri V, Stewart L, (1998) Extracting summary statistics to perform Meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-34.
20. Sutton AJ, Abrams KR, Jones DR, Sheldon TR. (2000) Methods for Meta-analysis in medical research. Wiley, Chichester.
21. Cao YF; Tan AH; Gao F; Liu LD; Liao C, et al. (2009) A Meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in Metastatic colorectal cancer. Int J Colorectal Dis 24(6): 677-85.
22. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-Line Metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16): 3697-705.
23. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for Metastatic breast cancer. N Engl J Med 357: 2666-76.
24. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Reprint-preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 89: 873-80.
25. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, et al. (2010) Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. J Clin Oncol 28(6): 911-917.
26. Pirker R, Pereira JR, Szczesna A, Pawel JV, Krzakowski M, et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 373: 1525-31.
27. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, et al. (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Annals of Oncology 19(2): 362-369.
28. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, et al. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-29.
29. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, et al. (2007) Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12): 1545-1552.
30. Mok TSK, Wu YL, Yu CJ, Zhou C, Chen YM, et al. (2009) Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 27(30): 5080-5087.
31. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 353(2): 123-32.
32. Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, et al. (2009) Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. J Clin Oncol 27(13): 2253-2260.
33. Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, et al. (2008) Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study. J Clin Oncol 26(26): 4253-4260.
34. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-37.
35. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, et al. (2008) Gefi tinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-18.
36. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K, et al. (2006) Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anti-Cancer Drugs 17: 401-409.
37. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, et al. (2008) Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 26: 4244-4252.
38. Lee DH, Park K, Kim JH, Lee JS, Shin SW, et al. (2010) Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy. Clin Cancer Res 16: 1307-1314.
39. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, et al. (2007) Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 25: 5777-5784.
40. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, et al. (2005) TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 23: 5892-5899.
41. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, et al. (2008) Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2. J Clin Oncol 26: 863-869.
42. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, et al. (2004) Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial-INTACT 1. J Clin Oncol 22: 777-784.
43. Takeda K, Hida T, Sato T, Ando M, Seto T, et al. (2010) Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). J Clin Oncol 28: 753-760.
44. Gaafar RM, Surmont VF, Scagliotti GV, Klaveren RJ, Papamichae D, et al. (2011) A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 47(15): 2331-40.
45. Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, et al. (2010) Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 70: 301-307.
46. Yang K, Wang YJ, Chen XR, Chen HN, (2010) Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 30(4): 229-41.
47. Manegold C, (2008) Bevacizumab for the treatment of advanced non-small-cell lung cancer. Anticancer Ther 8(5): 689-699.
48. Salanti G, Higgins JP, Ades AE, (2008) John PA Ioannidis. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 17: 279-301.